[Effect of alginate purity on microencapsulated hepatocyte overgrowth in peritoneal transplantation].
OBJECTIVE
To study the effect of alginate purity on microcapsule overgrowth in peritoneal transplantation.


METHODS
Alginate was purified by filtration and chloroform/butanol extraction. Using purified and crude alginate to make two kinds of microencapsulated hepatocytes (MHs), we transplanted 5 ml of each kind of MHs into the peritoneal cavities of rats. After 2 weeks, 1, 2, and 6 months, MHs were washed out to study overgrowth of MH, histology, enzyme and albumin of hepatocytes. Human lymphocytes transformation was measured by 3H-TdR incorporation with two kinds of alginate solutions.


RESULTS
The amount of retrieved MHs was larger in the purified than in the crude ( P < 0.01). In the purified groups, most hepatocytes had normal features of morphology, enzymatic histochemistry, and albumin immunohistochemistry staining after one month of transplantation, but were damaged in the crude groups only 2 weeks later. Microcapsules were smooth, regular and had no overgrowth during 6 months in the purified but overgrowth one month later after transplantation in the crude. The liquid scintillation counting (cpm) was lower in the purified than in the crude.


CONCLUSIONS
The purified alginate could reduce the overgrowth of MH and improve the function of hepatocytes significantly.
Yu
C
C
Department of Surgery, People's Hospital, Beijing Medical University, China.
Leng
X
X
Wei
Y
Y
Liu
J
J
Du
R
R
D000464:Alginates / Q000008:administration & dosage* / Q000737:chemistry / Q000302:isolation & purification; D000818:Animals; D002214:Capsules; D049109:Cell Proliferation; D020723:Glucuronic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000302:isolation & purification; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects / Q000637:transplantation*; D006603:Hexuronic Acids / Q000008:administration & dosage / Q000737:chemistry / Q000302:isolation & purification; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D010529:Peritoneal Cavity / Q000601:surgery; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D014183:Transplantation, Heterologous
D000464:Alginates; D002214:Capsules; D006603:Hexuronic Acids; D020723:Glucuronic Acid